These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17641441)

  • 1. Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes.
    Maegawa H; Nishio Y; Nakao K; Ugi S; Maeda K; Uzu T; Kashiwagi A
    Endocr J; 2007 Aug; 54(4):613-8. PubMed ID: 17641441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
    Fernandez M; Triplitt C; Wajcberg E; Sriwijilkamol AA; Musi N; Cusi K; DeFronzo R; Cersosimo E
    Diabetes Care; 2008 Jan; 31(1):121-7. PubMed ID: 17909084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
    Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
    J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.
    Karagiannis E; Pfützner A; Forst T; Lübben G; Roth W; Grabellus M; Flannery M; Schöndorf T
    Diabetes Technol Ther; 2008 Jun; 10(3):206-12. PubMed ID: 18473695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
    Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R
    Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
    Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.
    Martens FM; Visseren FL; de Koning EJ; Rabelink TJ
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):773-8. PubMed ID: 16306801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
    Martens FM; Rabelink TJ; op 't Roodt J; de Koning EJ; Visseren FL
    Eur Heart J; 2006 Jul; 27(13):1605-9. PubMed ID: 16762982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J; Fernandez M; Cervera A; Reyna S; Ghosh S; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.
    Clarke GD; Solis-Herrera C; Molina-Wilkins M; Martinez S; Merovci A; Cersosimo E; Chilton RJ; Iozzo P; Gastaldelli A; Abdul-Ghani M; DeFronzo RA
    Diabetes Care; 2017 Nov; 40(11):1530-1536. PubMed ID: 28847910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.
    Bi Y; Zhang B; Xu W; Yang H; Feng W; Li C; Tong G; Li M; Wang X; Shen S; Zhu B; Weng J; Zhu D
    Acta Diabetol; 2014 Oct; 51(5):865-73. PubMed ID: 25118999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.
    Wajcberg E; Sriwijitkamol A; Musi N; DeFronzo RA; Cersosimo E
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1256-62. PubMed ID: 17244785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes.
    Shand B; Scott R; Connolly S; Clarke R; Baker J; Elder P; Frampton C; Yeo J
    Diabetes Obes Metab; 2007 Jul; 9(4):540-7. PubMed ID: 17587396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
    Oda N; Imamura S; Fujita T; Uchida Y; Inagaki K; Kakizawa H; Hayakawa N; Suzuki A; Takeda J; Horikawa Y; Itoh M
    Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
    Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
    Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.